MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS

Patients with MYC-driven Group 3 medulloblastoma (MB) show particularly poor outcome. It was previously shown that MYC-driven MBs are highly sensitive to class I histone deacetylase inhibition (HDACi). We studied the molecular effects of the class I HDACi entinostat in MYC-driven MB cells to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Johanna, Ecker, Jonas, Hielscher, Thomas, Valinciute, Gintvile, Oppermann, Sina, Peterziel, Heike, Oehme, Ina, Witt, Olaf, Milde, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Medulloblastoma (Research)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715328/
http://dx.doi.org/10.1093/neuonc/noaa222.535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715328/
http://dx.doi.org/10.1093/neuonc/noaa222.535

Ejemplares similares